Debiopharm aims to develop innovative therapies that target high, unmet medical needs in oncology. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, clinically demonstrate their safety and efficacy, and then select large pharmaceutical commercialization partners to maximize patient access globally.
For over 40 years, we have been driven by the same commitment: bringing innovative solutions to patients.
Our story began in 1979 when Dr. Rolland-Yves Mauvernay, convinced that many useful therapeutic products were abandoned before reaching their full potential, decided to establish Debiopharm, a company dedicating to in-licensing innovative compounds and developing them into medicines for out-licensing. Having launched this unique business model with a staff of only 2 people, today, Debiopharm’s 420 employees are now active in a variety of roles within drug development, drug manufacturing and investment in digital health and smart data start-ups.
Together with his son Thierry Mauvernay, they were able to build a team of dedicated professionals with a broad range of expertise. Debiopharm specializes in 3 main activities including drug development (Debiopharm International), drug manufacturing (Debiopharm Research & Manufacturing) and digital health investment (Debiopharm Innovation Fund).